Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alanyl-tRNA synthetase (AlaRS) is an essential enzyme responsible for attaching alanine to its corresponding tRNA during protein synthesis. It belongs to the class IIc aminoacyl-tRNA synthetase family and plays a crucial role in maintaining the fidelity of translation. AlaRS possesses both aminoacylation and editing functions, ensuring that only the correct amino acid is incorporated into the growing polypeptide chain. It has a catalytic domain organized around an antiparallel beta sheet flanked by alpha helices, and mutations in related ARS enzymes can lead to human diseases.
Inhibition of tRNA aminoacylation, disruption of protein synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alanyl-tRNA Synthetase (AlaRS).